Compston Juliet
Department of Medicine, University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital, Box 157, Cambridge, CB2 2QQ, UK.
Curr Rheumatol Rep. 2004 Feb;6(1):66-9. doi: 10.1007/s11926-004-0085-1.
Osteoporosis is a common and serious complication of glucocorticoid therapy. Recent advances in the epidemiology, pathophysiology, and management of glucocorticoid-induced osteoporosis have stimulated the development of guidelines for the prevention and treatment of this condition. In this report, the updated recommendations of the American College of Rheumatology and guidelines recently produced by the Bone and Tooth Society, National Osteoporosis Society, and Royal College of Physicians in the UK are discussed with respect to their similarities and differences.
骨质疏松症是糖皮质激素治疗常见且严重的并发症。糖皮质激素性骨质疏松症在流行病学、病理生理学及管理方面的最新进展推动了该病症防治指南的制定。在本报告中，将讨论美国风湿病学会的最新建议以及英国骨与牙协会、国家骨质疏松协会和皇家内科医师学院近期制定的指南，比较它们的异同。
